Advertisement

Topics

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights

16:10 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Announced positive topline results for the first seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program. Treatment was well tolerated with 86% of patients achieving treatment success ...

Other Sources for this Article

At the Company:
Matthew Dansey
AmpliPhi Biosciences
(858) 800-4869
md@ampliphibio.com
or
Investor Relations:
Robert H. Uhl
Westwicke Partners
(858) 356-5932
robert.uhl@westwicke.com
or
Media:
David Schull or Maggie Beller
Russo Partners, LLC
(212) 845-4271
David.Schull@RussoPartnersLLC.com
Maggie.Beller@RussoPartnersLLC.com

NEXT ARTICLE

More From BioPortfolio on "AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...